Pfizer Inc. (NYSE:PFE) Stake Raised by LVM Capital Management Ltd. MI

LVM Capital Management Ltd. MI increased its stake in Pfizer Inc. (NYSE:PFE) by 10.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 268,753 shares of the biopharmaceutical company’s stock after purchasing an additional 26,072 shares during the quarter. Pfizer makes up 1.3% of LVM Capital Management Ltd. MI’s investment portfolio, making the stock its 29th largest holding. LVM Capital Management Ltd. MI’s holdings in Pfizer were worth $9,858,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of PFE. BancFirst Trust & Investment Management grew its stake in Pfizer by 2.3% during the 1st quarter. BancFirst Trust & Investment Management now owns 17,794 shares of the biopharmaceutical company’s stock valued at $719,000 after acquiring an additional 398 shares in the last quarter. Strategic Investment Advisors MI grew its stake in shares of Pfizer by 32.1% in the 1st quarter. Strategic Investment Advisors MI now owns 94,117 shares of the biopharmaceutical company’s stock valued at $3,840,000 after buying an additional 22,879 shares in the last quarter. State of Michigan Retirement System grew its stake in shares of Pfizer by 0.9% in the 1st quarter. State of Michigan Retirement System now owns 1,771,584 shares of the biopharmaceutical company’s stock valued at $72,281,000 after buying an additional 15,900 shares in the last quarter. MainStreet Investment Advisors LLC grew its stake in shares of Pfizer by 1.6% in the 1st quarter. MainStreet Investment Advisors LLC now owns 197,477 shares of the biopharmaceutical company’s stock valued at $8,057,000 after buying an additional 3,099 shares in the last quarter. Finally, Center For Asset Management LLC lifted its holdings in Pfizer by 28.0% in the 1st quarter. Center For Asset Management LLC now owns 23,894 shares of the biopharmaceutical company’s stock worth $975,000 after purchasing an additional 5,228 shares during the last quarter. Hedge funds and other institutional investors own 68.05% of the company’s stock.

Pfizer Trading Down 0.4 %

NYSE:PFE opened at $34.03 on Friday. Pfizer Inc. has a 1-year low of $33.54 and a 1-year high of $54.93. The business’s 50-day moving average price is $35.83 and its two-hundred day moving average price is $38.04. The company has a current ratio of 2.12, a quick ratio of 1.82 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $192.13 billion, a price-to-earnings ratio of 9.05, a PEG ratio of 1.14 and a beta of 0.59.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.10. The company had revenue of $12.73 billion for the quarter, compared to analyst estimates of $13.36 billion. Pfizer had a return on equity of 28.36% and a net margin of 27.55%. Pfizer’s revenue was down 54.1% compared to the same quarter last year. During the same quarter last year, the firm posted $2.04 earnings per share. On average, equities analysts expect that Pfizer Inc. will post 3.33 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 5th. Investors of record on Friday, July 28th were issued a dividend of $0.41 per share. The ex-dividend date was Thursday, July 27th. This represents a $1.64 dividend on an annualized basis and a dividend yield of 4.82%. Pfizer’s payout ratio is presently 43.62%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. JPMorgan Chase & Co. reduced their target price on Pfizer from $45.00 to $41.00 and set a “neutral” rating for the company in a report on Monday, July 17th. Morgan Stanley lowered their price target on Pfizer from $42.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Wednesday, August 2nd. Jefferies Financial Group decreased their target price on Pfizer from $40.00 to $38.00 in a report on Wednesday, August 2nd. BMO Capital Markets decreased their target price on Pfizer from $45.00 to $44.00 and set an “outperform” rating on the stock in a report on Wednesday, August 2nd. Finally, Credit Suisse Group lowered Pfizer from an “outperform” rating to a “neutral” rating and cut their price target for the company from $47.00 to $40.00 in a research note on Thursday, June 29th. Twelve research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $46.35.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.